Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.07
+0.54003.99%
Post-market: 14.05-0.0200-0.14%19:47 EDT
Volume:1.35M
Turnover:18.88M
Market Cap:570.71M
PE:-2.81
High:14.20
Open:13.42
Low:13.42
Close:13.53
Loading ...

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Traders Pull Back in Anticipation of More Inflation Data

MT Newswires Live
·
12 Dec 2024

Top Premarket Decliners

MT Newswires Live
·
12 Dec 2024

Keros Shares Dive on Halt to Trial of Pulmonary Hypertension Treatment

Dow Jones
·
12 Dec 2024

Keros Therapeutics Shares Drop After Voluntary Halt of Two Treatment Arms in TROPOS Trial

MT Newswires Live
·
12 Dec 2024

BRIEF-Keros Therapeutics Announces Update On The Phase 2 Tropos Trial

Reuters
·
12 Dec 2024

BUZZ-Keros Therapeutics plunges as dosing halted in trial due to safety concerns

Reuters
·
12 Dec 2024

Keros Therapeutics Shares Fall 44.6% Premarket After Halting Dosing in Trial of Experimental Drug for Rare Type of Blood Disorder

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics voluntarily halts dosing of blood pressure treatment after safety review

Reuters
·
12 Dec 2024

Keros Therapeutics provides update on Phase 2 TROPOS trial

TIPRANKS
·
12 Dec 2024

Keros Therapeutics Inc - Expects to Present Topline Data From All Treatment Arms in Trial Q2 2025

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics Inc - Halts Dosing in 3.0 Mg/Kg and 4.5 Mg/Kg Arms in Tropos Trial

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics Announces Update on the Phase 2 Tropos Trial

THOMSON REUTERS
·
12 Dec 2024

Keros Therapeutics Inc - Dosing in 1.5 Mg/Kg Arm of Tropos Trial Remains Ongoing

THOMSON REUTERS
·
12 Dec 2024

Wells Fargo Sticks to Its Buy Rating for Keros Therapeutics (KROS)

TIPRANKS
·
11 Dec 2024

Positive Clinical Updates and Promising Therapeutic Potential for Elritercept in MDS and MF: A Strong Case for Continued Development

TIPRANKS
·
11 Dec 2024

Keros Therapeutics presents clinical data from Elritercept program at ASH

TIPRANKS
·
10 Dec 2024

Strategic Partnership with Takeda Boosts Keros Therapeutics’ Growth Prospects and Financial Stability

TIPRANKS
·
06 Dec 2024

Strategic Advancements and Financial Gains Propel Keros Therapeutics’ Positive Outlook

TIPRANKS
·
06 Dec 2024

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

Benzinga
·
04 Dec 2024

BUZZ-Keros rises after blood cancer drug license deal with Takeda

Reuters
·
03 Dec 2024